For research use only
| Cat No. | ABC-TC0023 |
| Product Type | Human Melanoma Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Skin |
| Disease | Amelanotic Melanoma |
| Product Code | A 2058; A-2058 |
A2058 melanoma cells produce factors driving invasion and metastasis, making them key for studying melanoma progression and treatment response.
The A2058 cell line is a human malignant melanoma cell line derived from a lymph node metastasis of a 43-year-old Caucasian male patient. The cells display an epithelial-like morphology and exhibit adherent growth in monolayer culture. A2058 harbors the BRAF V600D mutation, a variant within the MAPK pathway commonly implicated in melanoma. The cells express invasion-associated proteins such as type IV collagenase, tissue inhibitor of metalloproteinase-2 (TIMP-2), laminin receptors, alongside elevated levels of nerve growth factor (NGF). A2058 is highly tumorigenic and metastatic, forming robust subcutaneous tumors in nude mice. The cell line is characterized by its high invasiveness in vitro, it serves as a valuable model for studying melanoma metastasis mechanisms.
| Product Code | A 2058; A-2058 |
| Species | Human |
| Cat.No | ABC-TC0023 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Skin |
| Disease | Amelanotic Melanoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Melanoma Cell Lines |
The A2058 cell line is a valuable tool in melanoma research, particularly for elucidating the molecular mechanisms underlying tumor invasion and metastasis. These cells express nerve growth factor (NGF) and laminin receptors which allows researchers to explore their roles in melanoma cell migration, adhesion, and interactions with the tumor microenvironment. A2058 cells are frequently employed in drug screening assays, signal transduction studies, and the development of targeted therapeutic strategies in melanoma management. The cell line’s relevance to primary and metastatic tumor behavior also supports its use in preclinical evaluation of novel anti-melanoma compounds.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
